KNG1 Protein (Transcript Variant 2)

Produktnummer ABIN2724258

Dieses Recombinant KNG1-Protein wird in HEK-293 Cells produziert.

Kurzübersicht für KNG1 Protein (Transcript Variant 2) (ABIN2724258)

Target: KNG1 (Kininogen 1 (KNG1))

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Antibody Production (AbP), Standard (STD)

Reinheit: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Produktdetails

Proteineigenschaft: Transcript Variant 2

Produktmerkmale:

• Recombinant human Kininogen-1 (transcript variant 2) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Endotoxin-Niveau: < 0.1 EU per μg protein as determined by LAL test

Anwendungsinformationen

Applikationshinweise: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Lyophilized from a 0.2 μM filtered solution of 20 mM Hac-NaAC, 150 mM NaCl, pH 4.0. Stable for at least 6 months from date of receipt under proper storage and handling conditions.

Lagerung: -80 °C

Informationen zur Lagerung: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Antigendetails

Target: KNG1 (Kininogen 1 (KNG1))

Andere Bezeichnung: Kininogen-1

Hintergrund: (1) Kininogens are inhibitors of thiol proteases (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action) (5) LMW-kininogen inhibits the aggregation of thrombocytes (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. [UniProtKB/Swiss-Prot Function]

Molekulargewicht: 46.9 kDa

NCBI Accession: NP_000884

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process